What is Pepticom?
Pepticom operates as a specialized technology firm focused on the development of novel peptide therapeutics through advanced biocomputational AI software. By leveraging machine learning algorithms to optimize the discovery process, the company effectively reduces the inherent risks and costs associated with pharmaceutical research and development. Their proprietary platform is engineered to identify superior binding peptides for complex target interactions, offering a distinct competitive advantage in the race to bring next-generation medicine to market. By facilitating both collaborative partnerships and internal discovery projects, Pepticom is actively shortening the development lifecycle for high-potential therapeutic compounds.
How much funding has Pepticom raised?
Pepticom has raised a total of $14.2M across 3 funding rounds:
Series A
$5M
Other Financing Round
$2.6M
Series A
$6.6M
Series A (2019): $5M with participation from Chartered Group
Other Financing Round (2021): $2.6M led by The Chartered Group
Series A (2025): $6.6M supported by Japan Israel High Tech Ventures 2 LP
Key Investors in Pepticom
Japan Israel High Tech Ventures 2 LP
A venture capital firm focused on fostering cross-border technological innovation between Japan and Israel, typically targeting high-growth sectors like biotech and deep tech.
The Chartered Group
A diversified investment firm with a global footprint, known for providing strategic capital to companies demonstrating significant potential in industrial and technological disruption.
What's next for Pepticom?
With the successful closure of this major enterprise-level funding, Pepticom is well-positioned to accelerate its R&D initiatives and broaden its portfolio of drug candidates. The strategic allocation of these funds will likely focus on enhancing the predictive accuracy of their AI models and scaling their discovery operations to meet the growing demand for precision medicine. As the company transitions into a more mature phase of its lifecycle, the focus will shift toward validating its lead candidates in preclinical settings and strengthening its intellectual property moat. Investors will be closely monitoring the firm's ability to translate its computational insights into tangible clinical outcomes, a critical step in establishing long-term value within the global biotech ecosystem.
See full Pepticom company page
